TREM2‐Mediated Cholesterol Efflux in Macrophages Inhibits Anti‐Tumor Immunity via Limitation of CD4 + T and NK Cells (Adv. Sci. 5/2026)

Advanced Science 2026 Open access

Read full text
Authors: Yunhan Wang, Weina Yu, Xinxin Wang, Qitai Zhao, Qingyang Lei, Aitian Li, Shasha Liu, Tian Wang, Li Yang, Yi Zhang
DOI: 10.1002/advs.73405
Cited by: 0

Abstract

Anti-Tumor Immunity TREM2+ TAMs promote tumor growth by suppressing anti-tumor immunity. Blockade of TREM2 reprograms macrophages, increases the infiltration and activity of CD4+ T and NK cells, thereby enhancing the anti-tumor responses. Bortezomib and ataluren, FDA-approved drugs, effectively enhance anti-tumor efficacy by inhibiting TREM2 to reshape the tumor microenvironment, indicating a potential therapeutic strategy for cancer. More details can be found in the Research Article by Li Yang, Yi Zhang, and co-workers (DOI: 10.1002/advs.202506995).

Fields of Study & Subjects

Immune cells in cancer Cancer Immunotherapy and Biomarkers Phagocytosis and Immune Regulation

Publication details

Journal / source
Advanced Science
Volume
13
Issue
5
Publication date
1 January 2026
Language
EN